UK Announces New Five-Year Voluntary Drug Pricing Deal
The VPAG includes a gradual rise in allowable branded medicine sales to the NHS and differentiated payment mechanisms for older and newer products. Industry will also commit to invest £400m in “pioneering” clinical trials, innovative manufacturing, and novel approaches to health technology assessments.
You may also be interested in...
An updated UK PharmaScan platform is to be delivered within the first three years of the new voluntary drug pricing scheme, with companies agreeing to provide “timely, accurate and comprehensive information” for all their medicines in development.
The UK’s new voluntary drug pricing and access deal is a “paradigm shift” that will see companies paying different levels of rebates depending on their product mix, with higher payments on older medicines making headroom for growth in newer drugs, according to one lawyer.
NHS England has committed to two pilots on innovative pricing models for advanced therapies under the UK’s new voluntary pricing agreement for new medicines.